{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:45:37Z","timestamp":1758361537238,"version":"3.44.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,19]]},"DOI":"10.7759\/cureus.92737","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T19:52:17Z","timestamp":1758311537000},"source":"Crossref","is-referenced-by-count":0,"title":["Silent Metastatic Pheochromocytoma: Clinical, Diagnostic, and Management Challenges in a Resource-Limited Setting"],"prefix":"10.7759","author":[{"given":"Bourhan","family":"Alrayes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nashaat  A","family":"Al-Shami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anas","family":"Hamedat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman","family":"Hijazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bishr","family":"Shibani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline","volume":"99","author":"Lenders JW","year":"2014","unstructured":"Lenders JW, Duh QY, Eisenhofer G, et al.. Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014, 99:1915-42. 10.1210\/jc.2014-1498","journal-title":"J Clin Endocrinol Metab"},{"key":"ref2","article-title":"Pathology and Genetics of Tumours of Endocrine Organs","author":"DeLellis RA","year":"2004","unstructured":"DeLellis RA. Pathology and Genetics of Tumours of Endocrine Organs. IARC Press, Lyon; 2004."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199405000-00015","article-title":"The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients","volume":"12","author":"Anderson GH Jr","year":"1994","unstructured":"Anderson GH Jr, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens. 1994, 12:609-15. 10.1097\/00004872-199405000-00015","journal-title":"J Hypertens"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4158\/EP.6.3.249","article-title":"Pheochromocytoma: clinical observations from a Brooklyn tertiary hospital","volume":"6","author":"Ariton M","year":"2000","unstructured":"Ariton M, Juan CS, AvRuskin TW. Pheochromocytoma: clinical observations from a Brooklyn tertiary hospital. Endocr Pract. 2000, 6:249-52. 10.4158\/EP.6.3.249","journal-title":"Endocr Pract"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.4.7392","article-title":"Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center","volume":"86","author":"Plouin PF","year":"2001","unstructured":"Plouin PF, Duclos JM, Soppelsa F, Boublil G, Chatellier G. Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center. J Clin Endocrinol Metab. 2001, 86:1480-6. 10.1210\/jcem.86.4.7392","journal-title":"J Clin Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2004.03.006","article-title":"Mortality associated with pheochromocytoma in a large Swedish cohort","volume":"30","author":"Khorram-Manesh A","year":"2004","unstructured":"Khorram-Manesh A, Ahlman H, Nilsson O, Od\u00e9n A, Jansson S. Mortality associated with pheochromocytoma in a large Swedish cohort. Eur J Surg Oncol. 2004, 30:556-9. 10.1016\/j.ejso.2004.03.006","journal-title":"Eur J Surg Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/1758-3284-2-23","article-title":"Malignant head and neck paragangliomas: is there an optimal treatment strategy?","volume":"2","author":"Moskovic DJ","year":"2010","unstructured":"Moskovic DJ, Smolarz JR, Stanley D, Jimenez C, Williams MD, Hanna EY, Kupferman ME. Malignant head and neck paragangliomas: is there an optimal treatment strategy?. Head Neck Oncol. 2010, 2:23. 10.1186\/1758-3284-2-23","journal-title":"Head Neck Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators","volume":"96","author":"Ayala-Ramirez M","year":"2011","unstructured":"Ayala-Ramirez M, Feng L, Johnson MM, et al.. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. 2011, 96:717-25. 10.1210\/jc.2010-1946","journal-title":"J Clin Endocrinol Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200205000-00002","article-title":"Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases","volume":"26","author":"Thompson LD","year":"2002","unstructured":"Thompson LD. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol. 2002, 26:551-66. 10.1097\/00000478-200205000-00002","journal-title":"Am J Surg Pathol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9020175","article-title":"Adrenocortical carcinoma: updates of clinical and pathological features after renewed World Health Organisation classification and pathology staging","volume":"9","author":"Lam AK","year":"2021","unstructured":"Lam AK. Adrenocortical carcinoma: updates of clinical and pathological features after renewed World Health Organisation classification and pathology staging. Biomedicines. 2021, 9:175. 10.3390\/biomedicines9020175","journal-title":"Biomedicines"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0113","article-title":"Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma","volume":"171","author":"Baudin E","year":"2014","unstructured":"Baudin E, Habra MA, Deschamps F, et al.. Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. Eur J Endocrinol. 2014, 171:R111-22. 10.1530\/EJE-14-0113","journal-title":"Eur J Endocrinol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-013-0320-x","article-title":"Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma","volume":"15","author":"Jimenez C","year":"2013","unstructured":"Jimenez C, Rohren E, Habra MA, Rich T, Jimenez P, Ayala-Ramirez M, Baudin E. Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. Curr Oncol Rep. 2013, 15:356-71. 10.1007\/s11912-013-0320-x","journal-title":"Curr Oncol Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.11.8034","article-title":"Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients","volume":"86","author":"Erickson D","year":"2001","unstructured":"Erickson D, Kudva YC, Ebersold MJ, Thompson GB, Grant CS, van Heerden JA, Young WF Jr. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab. 2001, 86:5210-6. 10.1210\/jcem.86.11.8034","journal-title":"J Clin Endocrinol Metab"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/107327481101800205","article-title":"Changing paradigms in the treatment of malignant pheochromocytoma","volume":"18","author":"Grogan RH","year":"2011","unstructured":"Grogan RH, Mitmaker EJ, Duh QY. Changing paradigms in the treatment of malignant pheochromocytoma. Cancer Control. 2011, 18:104-12. 10.1177\/107327481101800205","journal-title":"Cancer Control"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020152","article-title":"Germ-line mutations in nonsyndromic pheochromocytoma","volume":"346","author":"Neumann HP","year":"2002","unstructured":"Neumann HP, Bausch B, McWhinney SR, et al.. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002, 346:1459-66. 10.1056\/NEJMoa020152","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-13-0494","article-title":"Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma","volume":"21","author":"Kimura N","year":"2014","unstructured":"Kimura N, Takayanagi R, Takizawa N, et al.. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2014, 21:405-14. 10.1530\/ERC-13-0494","journal-title":"Endocr Relat Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2009.09.022","article-title":"Clinical spectrum of pheochromocytoma","volume":"209","author":"Guerrero MA","year":"2009","unstructured":"Guerrero MA, Schreinemakers JM, Vriens MR, et al.. Clinical spectrum of pheochromocytoma. J Am Coll Surg. 2009, 209:727-32. 10.1016\/j.jamcollsurg.2009.09.022","journal-title":"J Am Coll Surg"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1991.244","article-title":"Pheochromocytoma: new concepts and future trends","volume":"40","author":"Bravo EL","year":"1991","unstructured":"Bravo EL. Pheochromocytoma: new concepts and future trends. Kidney Int. 1991, 40:544-56. 10.1038\/ki.1991.244","journal-title":"Kidney Int"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.11.1427","article-title":"Biochemical diagnosis of pheochromocytoma: which test is best?","volume":"287","author":"Lenders JW","year":"2002","unstructured":"Lenders JW, Pacak K, Walther MM, et al.. Biochemical diagnosis of pheochromocytoma: which test is best?. JAMA. 2002, 287:1427-34. 10.1001\/jama.287.11.1427","journal-title":"JAMA"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021251","article-title":"A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines","volume":"88","author":"Sawka AM","year":"2003","unstructured":"Sawka AM, Jaeschke R, Singh RJ, Young WF Jr. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab. 2003, 88:553-8. 10.1210\/jc.2002-021251","journal-title":"J Clin Endocrinol Metab"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-19-0165","article-title":"Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups","volume":"26","author":"Ta\u00efeb D","year":"2019","unstructured":"Ta\u00efeb D, Jha A, Treglia G, Pacak K. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. Endocr Relat Cancer. 2019, 26:R627-52. 10.1530\/ERC-19-0165","journal-title":"Endocr Relat Cancer"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04398-1","article-title":"European Association of Nuclear Medicine Practice Guideline\/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma","volume":"46","author":"Ta\u00efeb D","year":"2019","unstructured":"Ta\u00efeb D, Hicks RJ, Hindi\u00e9 E, et al.. European Association of Nuclear Medicine Practice Guideline\/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2019, 46:2112-37. 10.1007\/s00259-019-04398-1","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0739","article-title":"Phase II randomized trial comparing high-dose IFN-\u03b12b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma","volume":"19","author":"Lian B","year":"2013","unstructured":"Lian B, Si L, Cui C, et al.. Phase II randomized trial comparing high-dose IFN-\u03b12b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma. Clin Cancer Res. 2013, 19:4488-98. 10.1158\/1078-0432.CCR-13-0739","journal-title":"Clin Cancer Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/390952-silent-metastatic-pheochromocytoma-clinical-diagnostic-and-management-challenges-in-a-resource-limited-setting","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T19:52:18Z","timestamp":1758311538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/390952-silent-metastatic-pheochromocytoma-clinical-diagnostic-and-management-challenges-in-a-resource-limited-setting"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.92737","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,9,19]]}}}